Neutropenia News and Research

RSS

Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils, the most important type of white blood cell, in the blood.

Millennium announces data on VELCADE in treatment of patients with amyloidosis

Millennium: The Takeda Oncology Company today announced data examining the use of VELCADE in the treatment of patients with relapsed or refractory light chain (AL) amyloidosis. Amyloidosis is a rare condition in which excessive proteins build up in organs or tissues, such as the heart, kidney or liver. These data were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Illinois, June 4-8, 2010.

5 Jun 2010

Amgen to present Phase 2 study data of AMG 479 in metastatic pancreatic cancer at 2010 ASCO

Amgen today announced results from a small, randomized, placebo-controlled Phase 2 study indicating that adding AMG 479 to gemcitabine improved overall survival at six months (primary endpoint) and progression-free survival in patients with metastatic pancreatic cancer. The study, which also included a separate arm of conatumumab plus gemcitabine, is being presented in a Poster Discussion at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting.

5 Jun 2010

Vandetanib in combination with chemotherapy improves progression-free survival in patients with lung cancer

When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas MD Anderson Cancer Center.

5 Jun 2010

Onyx presents interim results of Phase 1b dose-escalation carfilzomib combination trial for multiple myeloma

Onyx Pharmaceuticals, Inc. today announced updated interim results of the Phase 1b dose-escalation trial, known as the 006 study, evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed and/or refractory myeloma. These data are being presented today at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

5 Jun 2010

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy.

4 Jun 2010

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.

4 Jun 2010

Allos Therapeutics' FOLOTYN data to be presented at 46th ASCO and 15th EHA Congress

Allos Therapeutics, Inc. today announced that data on FOLOTYN® (pralatrexate injection) will be presented at two upcoming medical conferences: the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), which will be held June 4-8 in Chicago, Illinois, and at the 15th Congress of the European Hematology Association (EHA), which will be held June 10-13 in Barcelona, Spain.

2 Jun 2010

US District Court dismisses all claims and counterclaims in thalidomide patent cases

Celgene Corporation announced that as a result of Barr Laboratories, Inc., withdrawing its Abbreviated New Drug Application (ANDA) for thalidomide with the US Food and Drug Administration, the US District Court for the District of New Jersey has granted the requested dismissal of all claims and counterclaims in the thalidomide patent cases.

27 May 2010

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

Abraxis BioScience, Inc., a fully integrated biotechnology company, previously announced it will be presenting more than 30 studies, including new clinical data evaluating the use of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable suspension; paclitaxel protein albumin-bound particles for injectable suspension) for the treatment of pancreatic cancer at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago.

21 May 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Pfizer Oncology will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology meeting in Chicago from June 4-8.

21 May 2010

Nektar Therapeutics to present data of NKTR-102 Phase 2 clinical trial in ovarian cancer at 46th ASCO

Nektar Therapeutics today announced that results from the Phase 2 clinical trial of NKTR-102 in women with platinum-resistant/refractory ovarian cancer will be presented at the Oral Abstract Session of the Gynecologic Cancer Track during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).

21 May 2010

Eli Lilly to present results of two Phase II trials evaluating ALIMTA in combination with chemotherapy, radiation

Results of two Phase II trials evaluating ALIMTA (pemetrexed for injection) in combination with a platinum chemotherapy and radiation for patients with locally advanced non-small cell lung cancer will be presented by Eli Lilly and Company at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago, Ill., on June 6, 2010.

21 May 2010

Phase II study results of Lilly Oncology's tasisulam for metastatic melanoma to be presented at 46th ASCO

Lilly released results today from a Phase II study evaluating Lilly Oncology's tasisulam, a novel anti-cancer agent, in patients with metastatic melanoma, the deadliest form of skin cancer. Study results will be presented during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. on June 6, 2010.

21 May 2010

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Takeda Pharmaceutical Company Limited and its wholly owned subsidiary Millennium: The Takeda Oncology Company today announced that Takeda has entered into a co-promotion agreement with Janssen Pharmaceutical K.K. for VELCADE® (bortezomib) for Injection, a treatment for patients with multiple myeloma.

10 May 2010

Telik first-quarter net loss decreases to $5.3 million

Telik, Inc. today reported financial results for the first quarter ended March 31, 2010. The net loss for the quarter ended March 31, 2010 was $5.3 million, or $0.10 per share, compared with a net loss of $7.7 million, or $0.14 per share, for the same period in 2009.

7 May 2010

Allos Therapeutics reports net loss of $20.5 million for first-quarter 2010

Allos Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2010.

6 May 2010

ABRAXANE-bevacizumab combination therapy may exhibit potential in treatment of triple-negative breast cancers

Abraxis BioScience, Inc., a fully integrated biotechnology company, announced study results today that demonstrate a regimen of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) given in combination with bevacizumab (Avastin®) may have potential in the treatment of triple-negative breast cancers.

21 Apr 2010

Updated survival data from Phase I/II trial of nab-paclitaxel, gemcitabine combination for pancreatic cancer

Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced updated overall survival findings from a phase I/II study of nab®-paclitaxel (ABRAXANE® for Injectable Suspension) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) given in combination with gemcitabine, demonstrated increased survival of the first-line treatment of patients with advanced pancreatic cancer.

19 Apr 2010

Phase II study: Hepatitis C patients receiving ANA598 bid plus SOC attain undetectable levels of virus

Anadys Pharmaceuticals, Inc. announced today that 72% of hepatitis C patients receiving ANA598 400 mg twice daily (bid) plus standard of care achieved undetectable levels of virus at week eight in an ongoing Phase II study, compared to 38% of patients receiving placebo plus SOC.

19 Apr 2010

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Findings published today in The New England Journal of Medicine from a first-of-its-kind comparator trial evaluating the anti-tumor necrosis factor (TNF)-alpha biologic treatment REMICADE (infliximab) in the treatment of moderately to severely active Crohn's disease in patients who were naive to immunomodulator and biologic therapy, showed that a significantly greater proportion of patients receiving REMICADE achieved steroid-free remission and mucosal healing compared with patients receiving azathioprine.

16 Apr 2010

Neutropenia News and Research

Further Reading

Millennium announces data on VELCADE in treatment of patients with amyloidosis

Amgen to present Phase 2 study data of AMG 479 in metastatic pancreatic cancer at 2010 ASCO

Vandetanib in combination with chemotherapy improves progression-free survival in patients with lung cancer

Onyx presents interim results of Phase 1b dose-escalation carfilzomib combination trial for multiple myeloma

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Allos Therapeutics' FOLOTYN data to be presented at 46th ASCO and 15th EHA Congress

US District Court dismisses all claims and counterclaims in thalidomide patent cases

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Nektar Therapeutics to present data of NKTR-102 Phase 2 clinical trial in ovarian cancer at 46th ASCO

Eli Lilly to present results of two Phase II trials evaluating ALIMTA in combination with chemotherapy, radiation

Phase II study results of Lilly Oncology's tasisulam for metastatic melanoma to be presented at 46th ASCO

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Telik first-quarter net loss decreases to $5.3 million

Allos Therapeutics reports net loss of $20.5 million for first-quarter 2010

ABRAXANE-bevacizumab combination therapy may exhibit potential in treatment of triple-negative breast cancers

Updated survival data from Phase I/II trial of nab-paclitaxel, gemcitabine combination for pancreatic cancer

Phase II study: Hepatitis C patients receiving ANA598 bid plus SOC attain undetectable levels of virus

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News